Walleye Trading LLC Purchases New Position in Outset Medical, Inc. (NASDAQ:OM)

Walleye Trading LLC acquired a new position in Outset Medical, Inc. (NASDAQ:OMGet Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,728 shares of the company’s stock, valued at approximately $249,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bellevue Group AG grew its position in shares of Outset Medical by 259.8% during the 1st quarter. Bellevue Group AG now owns 2,017,159 shares of the company’s stock valued at $91,579,000 after acquiring an additional 1,456,553 shares during the period. C WorldWide Group Holding A S purchased a new position in Outset Medical during the second quarter worth approximately $11,145,000. Bank of New York Mellon Corp grew its holdings in Outset Medical by 29.5% in the first quarter. Bank of New York Mellon Corp now owns 944,557 shares of the company’s stock valued at $42,883,000 after purchasing an additional 215,365 shares during the period. Vanguard Group Inc. increased its position in shares of Outset Medical by 4.6% in the first quarter. Vanguard Group Inc. now owns 4,324,072 shares of the company’s stock valued at $196,313,000 after buying an additional 190,158 shares in the last quarter. Finally, Champlain Investment Partners LLC increased its position in shares of Outset Medical by 9.3% in the first quarter. Champlain Investment Partners LLC now owns 2,046,685 shares of the company’s stock valued at $92,919,000 after buying an additional 174,030 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on OM shares. Morgan Stanley dropped their price target on shares of Outset Medical from $19.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 10th. Cowen dropped their target price on shares of Outset Medical to $22.00 in a research report on Tuesday. Royal Bank of Canada began coverage on shares of Outset Medical in a research report on Friday, November 11th. They set an “outperform” rating and a $23.00 price target for the company. The Goldman Sachs Group decreased their price target on shares of Outset Medical from $34.00 to $29.00 and set a “buy” rating on the stock in a research note on Wednesday, November 9th. Finally, Cowen cut their price objective on Outset Medical from $33.00 to $22.00 in a research note on Wednesday, November 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.83.

Insider Transactions at Outset Medical

In other Outset Medical news, CEO Leslie Trigg sold 30,000 shares of the firm’s stock in a transaction on Friday, November 11th. The stock was sold at an average price of $20.00, for a total value of $600,000.00. Following the completion of the sale, the chief executive officer now directly owns 291,159 shares of the company’s stock, valued at approximately $5,823,180. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Outset Medical news, CEO Leslie Trigg sold 30,000 shares of the business’s stock in a transaction dated Friday, November 11th. The shares were sold at an average price of $20.00, for a total value of $600,000.00. Following the transaction, the chief executive officer now directly owns 291,159 shares in the company, valued at approximately $5,823,180. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Martin Vazquez sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, November 11th. The stock was sold at an average price of $20.00, for a total transaction of $300,000.00. Following the sale, the chief operating officer now owns 49,550 shares of the company’s stock, valued at approximately $991,000. The disclosure for this sale can be found here. Insiders have sold a total of 45,131 shares of company stock worth $901,968 in the last ninety days. Insiders own 4.00% of the company’s stock.

Outset Medical Stock Performance

OM opened at $18.55 on Friday. Outset Medical, Inc. has a twelve month low of $11.41 and a twelve month high of $53.07. The firm has a market capitalization of $896.11 million, a PE ratio of -5.77 and a beta of 1.60. The company has a current ratio of 6.24, a quick ratio of 5.13 and a debt-to-equity ratio of 0.11. The firm’s 50-day moving average price is $15.83 and its 200 day moving average price is $18.43.

Outset Medical Company Profile

(Get Rating)

Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.

See Also

Institutional Ownership by Quarter for Outset Medical (NASDAQ:OM)

Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.